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INTRODUCTION
According to classical concepts of pharmacology, competitive receptor antagonists occupy the ligand binding site and 'antagonize' receptor activity by precluding agonist binding:
"In competitive antagonism, agonist and antagonist, simultaneously present in solution, are each considered to compete for receptors to the exclusion of the other…" (Stephenson, 1956 ). This notion of blockade of G-protein coupled receptor (GPCR) activation by "steric hindrance" has been supported by recent crystallographic studies of the β-adrenergic receptor showing that agonists and antagonists occupy overlapping (but not identical) binding sites (Rosenbaum et al., 2007; Rosenbaum et al., 2011; Warne et al., 2011) . The notion that some GPCR antagonists can also stabilize the inactive state of the receptor, and thereby function as inverse agonists, was first put forth by Costa and Herz in studies of opioid receptors (Costa and Herz, 1989) . It is now well accepted that so-called antagonists could have negative intrinsic activity and thus function as inverse agonists, or lack activity and thus function as neutral antagonists. By definition, however, an 'antagonist' is devoid of efficacy.
Contradicting these fundamental notions of pharmacology have been observations dating to the late 1970s that some so-called 'antagonists' can display various patterns of efficacy. Thus, Bergstrom and Kellar (Bergstrom and Kellar, 1979) and Peroutka and Snyder (Peroutka and Snyder, 1980) showed that chronic including typical and atypical antipsychotic drugs (Andree et al., 1986) , typical and atypical antidepressants (Blackshear and Sanders-Bush, 1982; Brunello et al., 1982) , and even relatively selective 5-HT 2A antagonists (Leysen et al., 1986) . There have also been reports that some 5-HT 2A antagonists can up-regulate 5-HT 2A receptors after chronic administration (Rinaldi-Carmona et al., 1993) or have no effect (Gray and Roth, 2001 ). Antagonist-induced 5-HT 2A down-regulation might have therapeutic relevance (Elphick et al., 2004; Harvey et al., 2004; O'Connor and Roth, 2005) . We now know that antagonist-induced receptor down-regulation can be readily explained by the concept of functional selectivity (Urban et al., 2007) or biased agonism (Galandrin et al., 2007 ) (Roth and Chuang, 1987) .
The mechanism(s) responsible for the paradoxical antagonist-induced receptor "down-regulation" are still unclear. Several studies have demonstrated that 5-HT 2A
antagonists can induce receptor internalization in vitro (Berry et al., 1996; Willins et al., 1999; Bhatnagar et al., 2001 ) and in vivo (Willins et al., 1998; Willins et al., 1999) .
Additionally receptor down-regulation is apparently independent of changes in receptor gene transcription (Roth and Ciaranello, 1991) . Two independent studies have indicated that antagonist-induced internalization occurs via clathrin-dependent processes in vitro (Bhatnagar et al., 2001; Hanley and Hensler, 2002 (Costall and Naylor, 1995; Martin et al., 1997) . Likewise for ketanserin the dose chosen (10 mg/kg) exceeds the effective dose for normalization of MK801-induced hyperactivity (0.12 mg/kg) (O'Neill et al., 1998) and was the maximum tolerated dose for this drug. For altanserin we chose a dose of 10 mg/kg which was the maximum tolerated dose and in excess of that previously used for behavioral studies of 5-HT2A receptors (0.5 mg/kg) (Stoessl et al., 1990) . For pimavanserin, the dose chosen (5 mg/kg) was the maximum tolerated dose and again exceeded the dose used previously in behavioral studies (3 mg/kg)(Horiguchi et al., Nonspecific binding was determined by incubating the reactions with 10 μM ritanserin.
Reactions were harvested by vacuum filtration through glass filters (3X ice-cold 50 mM Tris, pH 7.4; pH 6.9 at room temperature) and measured by liquid scintillation using a Perkin-Elmer Tri-Carb 2800TR scintillation counter. Non-linear saturation analysis was done using Graphpad Prism 4.01 to obtain B max values, and Bradford protein assays were (Bio-Rad, Hercules, CA) performed in order to normalize B max determinations to the amount of protein in each assay. 
Locomotor and stereotypic activity
Locomotor activity was assessed in photocell-based activity chambers under standardized environmental conditions, using an AccuScan activity monitor (AccuScan down-regulation (ketanserin) or no effect (M100907, altanserin, pimavanserin, MDL11939). SR46349B-mediated up-regulation was associated with a potentiation of PCP-induced locomotor responses (Fig. 5G) , whereas chronic pimavanserin treatment had no effect (Fig. 5H ).
RESULTS
Olanzapine and clozapine but not haloperidol down-regulate 5-HT
This article has not been copyedited and formatted. The final version may differ from this version. for dopamine, serotonin, muscarinic, adrenergic receptors . Thus, it is quite complicated and the subject considerable controversy to explain unique salutary effects of clozapine and other related atypicals Allen and Roth, 2011) .
Interestingly, chronic treatment with three candidate antipsychotic drugs (M100907, SR46349B and pimavanserin) either had no effect (M100907, pimavanserin)
or up-regulated 5-HT 2A receptors. It is interesting in this regard that not only did none of these drugs attenuate PCP's hyperlocomotive ability, but also that none of these drugs displayed efficacy in large-scale Phase III clinical trials. Taken together, these findings are consistent with the notion that down-regulation of 5-HT 2A receptors may be important for certain therapeutic actions of atypical antipsychotic drugs. However, atypical antipsychotic clozapine and olanzapine have marked polypharmacology, with affinities for dopamine, serotonin, muscarinic, adrenergic receptors .
Thus, it is quite complicated and the subject of considerable controversy to explain unique salutary effects of clozapine and other related atypicals (Allen and Roth, 2011) .
The most important implication of these findings is the clear-cut evidence in favor of the hypothesis that antagonists display unique patterns of functional selectivity. The precise molecular mechanisms responsible for the paradoxical down-regulation of 5-HT 2A receptors in vivo is currently unknown and are the topic of intensive research at present (Yadav et al, in preparation) .
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